YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World’s First In Vivo Gene Editing Therapy for PH1

Posted on by

SHANGHAI, Aug. 22, 2024 /PRNewswire/ — YolTech Therapeutics, a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures, today announced a major milestone: the first patient has been dosed with YOLT-203, the company’s cutting-edge in vivo genome editing…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.